Comparing Bioverativ (BIVV) and Tyme Technologies (TYME)

Bioverativ (NASDAQ: BIVV) and Tyme Technologies (NASDAQ:TYME) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends and valuation.

Institutional and Insider Ownership

100.0% of Bioverativ shares are owned by institutional investors. Comparatively, 2.4% of Tyme Technologies shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.


This table compares Bioverativ and Tyme Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Bioverativ 30.43% 40.99% 22.79%
Tyme Technologies N/A -219.60% -152.87%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Bioverativ and Tyme Technologies, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bioverativ 0 13 3 0 2.19
Tyme Technologies 0 0 3 0 3.00

Bioverativ presently has a consensus target price of $63.25, suggesting a potential downside of 39.07%. Tyme Technologies has a consensus target price of $8.25, suggesting a potential upside of 140.52%. Given Tyme Technologies’ stronger consensus rating and higher possible upside, analysts clearly believe Tyme Technologies is more favorable than Bioverativ.

Valuation & Earnings

This table compares Bioverativ and Tyme Technologies’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bioverativ $1.17 billion 9.61 $355.60 million $2.74 37.89
Tyme Technologies N/A N/A -$15.20 million ($0.17) -20.18

Bioverativ has higher revenue and earnings than Tyme Technologies. Tyme Technologies is trading at a lower price-to-earnings ratio than Bioverativ, indicating that it is currently the more affordable of the two stocks.


Bioverativ beats Tyme Technologies on 8 of the 10 factors compared between the two stocks.

Bioverativ Company Profile

Bioverativ Inc. (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor thereby making the product last longer in a person’s blood than various factor therapies. Its pipeline includes BIVV 001(rFVIIIFc-VWF-XTEN) and BIVV 002 (rFIXFc-XTEN).

Tyme Technologies Company Profile

Tyme Technologies, Inc. is a clinical-stage biotechnology company. The Company is focused on developing cancer therapeutics that is intended to be broadly effective across tumor types and have low toxicity profiles. The Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system. The Company’s lead clinical program, SM-88, is a first-in-class combination therapy in Phase II development for prostate cancer, and it is preparing to initiate an additional Phase II clinical trial for pancreatic cancer. The Company provides a novel compound for physicians to use in a treatment regimen for patients fighting six major cancers including breast, lung, prostate, gastric, esophageal and pancreatic cancers.

Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with's FREE daily email newsletter.

Leave a Reply